Clinical Scorecard: Linking APOBEC-Induced Mutagenesis to Changes in Stromal and Endothelial Microenvironments and Alterations in PCDH9-Related Signaling in Colorectal Cancer

At a Glance

Key Highlights

• APOBEC activation correlates with worse survival in colorectal cancer.
• High APOBEC activation tumors show increased fibroblast and endothelial signatures.
• APOBEC3B activation is linked to endothelial transcriptional remodeling.
• PCDH9 identified as a candidate target linked to multiple signaling pathways.
• APOBEC-high tumors may be candidates for anti-angiogenic therapy.

Guideline-Based Recommendations

Diagnosis

• Utilize whole-exome sequencing and transcriptomics for comprehensive evaluation.

Management

• Consider targeting APOBEC-induced signaling vulnerabilities in treatment strategies.

Monitoring & Follow-up

• Monitor APOBEC activation levels as a prognostic biomarker.

Risks

• High APOBEC activity is associated with increased risk of metastasis and treatment resistance.

Patient & Prescribing Data

Patients with primary colorectal cancer undergoing surgical resection.

APOBEC-high tumors may benefit from anti-angiogenic therapies.

Clinical Best Practices

• Integrate multi-omics data for a comprehensive understanding of tumor biology.
• Conduct survival analysis and multivariable regression to identify prognostic factors.

Related Resources & Content